Lu AA41063 is a selective adenosine A<sub>2A</sub> receptor antagonist. Structurally, it is a non-xanthine.
The affinities (K<sub>i</sub>) of the drug for the human adenosine receptors are 5.9nM for the adenosine A<sub>2A</sub> receptor, 410nM for the adenosine A<sub>1</sub> receptor (69-fold lower than for the A<sub>2A</sub> receptor), 260nM for the adenosine A<sub>2B</sub> receptor (44-fold lower than for the A<sub>2A</sub> receptor), and >10,000nM for the adenosine A<sub>3</sub> receptor (>1,695-fold lower than for the A<sub>2A</sub> receptor).
Lu AA41063 was first described in the scientific literature by 2014.
Lu AA47070, a water-soluble phosphate ester prodrug of Lu AA41063, is orally active and was under development for the treatment of Parkinson's disease but was discontinued. In addition to its antiparkinsonian-like effects, Lu AA47070 reverses motivational deficits in animals and hence shows pro-motivational effects.